NCT06714916Recruiting
Optimising Renal Tumour Management Through Artificial Intelligence Modules
Mutimodal Artificial Intelligence for Optimising Renal Tumour Management: Diagnosis, Surgery and Prognosis
Source: ClinicalTrials.gov · Last updated 19 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are: 1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images. 2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor. 3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival. Participants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2100 (estimated)
- First submitted
- 2 Dec 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Shao Pengfei
- Diseases
- Kidney cancer
- NCT number
- NCT06714916
What you commit to
- Study type: Observational
- Planned participants: 2100
- From 1 Jan 2025 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment in any form, including surgery, targeted therapy and immunotherapy;
Other
- Patients with any item missing from the baseline clinical and pathological information;
- Patients who has already metastasized by the time the tumor is discovered;
Who the study is looking for
- Patients with renal tumor which can be treated by surgery;
- Complete CECT within 30 days before surgery;
- Patients who fully understand this study and sign the informed consent;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.